Latham & Watkins Advises Gossamer Bio in Option Agreement to Acquire Respira Therapeutics

Gossamer Bio, Inc. (Nasdaq: GOSS), a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), announced it has entered into an option agreement to acquire Respira Therapeutics (Respira) and its lead product candidate, RT234.

Latham & Watkins LLP represents Gossamer Bio in the transaction with a corporate team led by San Diego partners Kevin Reyes, Matt Bush, and Steve Chinowsky, with associates Dylan Towns and Madeline Hodges. Advice was also provided on intellectual property matters by San Diego associate Kristina Funahashi; on tax matters by Houston partner Jared Grimley, with associate Lucas Migliano; on benefits matters by San Diego partner Holly Bauer and Orange County counsel Sara Schlau, with associate Julie Voorhes; on public company matters by San Diego associate Shelby Harrison; on FDA/healthcare matters by Bay Area partner Betty Pang and Washington, D.C. counsel Chad Jennings; and on data privacy and cybersecurity matters by Bay Area partner Heather Deixler, with associate Kathryn Parsons-Reponte.